The Hub for Disease-Specific Clinical Information
Advertisement
Advertisement

Allogeneic CAR T-Cell Therapy to Enter Phase I Trial in Multiple Myeloma

By: Sarah Jackson
Posted: Thursday, April 11, 2019

The U.S. Food and Drug Administration (FDA) approved an investigational new drug application to initiate a phase I clinical trial in multiple myeloma for UCARTCS1, reportedly the first allogeneic chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma to enter clinical development. The investigational new drug application for UCARTCS1 was filed on December 28, 2018, and approved by the FDA within a month, on January 25, 2019.

UCARTCS1 is an allogeneic, off-the-shelf, gene-edited T-cell product candidate designed for the treatment of multiple myeloma. It is based on a tailored manufacturing process that removes both the CS1 antigen and the T-cell receptor from the T-cell surface using gene-editing technology before adding the CS1 CAR construct. The UCART is designed to have a lymphodepleting effect, and the CAR T-cell cross reaction is suppressed.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.